Binding of natural and synthetic inhibitors to human heat shock protein 90 and their clinical application

Medicina

Volumn 47, Issue 8, 2011, Pages 413-420

  Petrikaite, Vilma ^a   Matulis, Daumantas ^a  

^a VILNIUS UNIVERSITY   (Lithuania)

Author keywords

Anticancer activity; Hsp90 inhibitors; Isothermal titration calorimetry; Thermal shift assay; ThermoFluor

Indexed keywords

EID: 84856634624     PISSN: 1010660X     EISSN: None     Source Type: Journal    
DOI: 10.3390/medicina47080062     Document Type: Review

References (57)

1. Welch WJ, Feramisco JR. Purification of the major mammalian heat shock proteins. J Biol Chem 1982;24(257):14949-59.
2. Pearl LH, Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem 2006;75:271-94.
3. Wandinger SK, Richter K, Buchner J. The Hsp90 chaperone machinery. J Biol Chem 2008;283:18473-7.
4. Taldone T, Gozman A, Maharaj R, Chiosis G. Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol 2008;8(4):370-4.
5. Biamonte MA, Van de Water R, Arndt JW, Scannevin RH, Perret D, Lee W. Heat shock protein 90: inhibitors in clinical trials. J Med Chem 2010;53:3-17.
6. Porter JR, Ge J, Lee J, Normant E, West K. Ansamycin inhibitors of Hsp90: nature's prototype for anti-chaperone therapy. Curr Topics Med Chem 2009;9:1386-418.
7. Sharp SY, Boxall K, Rowlands M, Prodromou C, Roe SM, Maloney A, et al. In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors. Cancer Res 2007;67(5):2206-16.
8. Taldone T, Sun W, Chiosis G. Discovery and development of heat shock protein 90 inhibitors. Bioorg Med Chem 2009;17(6):2225-35.
9. Ladbury JE, Klebe G, Freire E. Adding calorimetric data to decision making in lead discovery: a hot tip. Nat Rev Drug Discov 2010;9(1):23-7.
10. Hickey E, Brandon SE, Smale G, Lloyd D, Weber LA. Sequence and regulation of a gene encoding a human 89-kilodalton heat shock protein. Mol Cell Biol 1989;9(6):2615-26.
11. Buchner J. Bacterial Hsp90 - desperately seeking client. Mol Microbiol 2010;76(3):540-4.
12. Acharya P, Kumar R, Tatu U. Chaperoning a cellular upheaval in malaria: heat shock proteins in Plasmodium falciparum. Mol Biochem Parasitol 2007;153:85-94.
13. Rutherford SL, Lindquist S. Hsp90 as a capacitor for morphological evolution. Nature 1998;396(6709):336-42.
14. Chen B, Zhong D, Monteiro A. Comparative genomics and evolution of the HSP90 family of genes across all kingdoms of organisms. BMC Genomics 2006;7:156.
15. Ali MM, Roe SM, Vaughan CK, Meyer P, Panaretou B, Piper PW, et al. Crystal structure of an Hsp90-nucleotide-p23/sba1 closed chaperone complex. Nature 2006;440(7087):1013-7.
16. Solit DB, Chiosis G. Development and application of Hsp90 inhibitors. Drug Discov Today 2008;13:38-43.
17. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-pp60vsrc heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. PNAS 1994;91(18):8324-8.
18. Fukuyo Y, Hunt CR, Horikoshi N. Geldanamycin and its anti-cancer activities. Cancer Lett 2010;290(1):24-35.
19. Supko JG, Hickman RL, Grever MR, Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 1995;36:305-15.
20. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003; 425(6956):407-10.
21. Ronnen EA, Kondagunta GV, Ishill N, Sweeney SM, Deluca JK, Schwartz L, et al. A phase II trial of 17-(allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs 2006; 24(6):543-6.
22. Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, Bagatell R, et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007;25:5410-7.
23. Soga S, Shiotsu Y, Akinaga S, Sharma SV. Development of radicicol analogues. Curr Cancer Drug Targets 2003;3:359-69.
24. Chiosis G, Lucas B, Shtil A, Huezo H, Rosen N. Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase. Bioorg Med Chem 2002;10(11):3555-64.
25. Chiosis G, Timaul MN, Lucas B, Munster PN, Zheng FF, Sepp-Lorenzino L, et al. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem Biol 2001;8(3):289-99.
26. Taldone T, Chiosis G. Purine-scaffold Hsp90 inhibitors. Curr Top Med Chem 2009;9(15):1436-46.
27. Lundgren K, Zhang H, Brekken J, Huser N, Powell RE, Timple N, et al. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther 2009;8(4):921-9.
28. Cheung KM, Matthews TP, James K, Rowlands MG, Boxall KJ, Sharp SY, et al. The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorg Med Chem Lett 2005;15(14):3338-43.
29. Brough PA, Aherne W, Barril X, Borgognoni J, Boxall K, Cansfield JE, et al. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem 2008;51(2):196-218.
30. Gaspar N, Sharp SY, Eccles SA, Gowan S, Popov S, Jones C, et al. Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma. Mol Cancer Ther 2010;9(5):1219-33.
31. Woodhead AJ, Angove H, Carr MG, Chessari G, Congreve M, Coyle JE, et al. Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J Med Chem 2010;53(16):5956-69.
32. Kim YS, Alarcon SV, Lee S, Lee MJ, Giaccone G, Neckers L, et al. Update on Hsp90 inhibitors in clinical trial. Curr Topics Med Chem 2009;9:1479-92.
33. Huang KH, Veal JM, Fadden RP, Rice JW, Eaves J, Strachan JP, et al. Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. J Med Chem 2009;52(14):4288-305.
34. Brough PA, Barril X, Borgognoni J, Chene P, Davies NG, Davis B, et al. Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. J Med Chem 2009;52(15):4794-809.
35. Kung PP, Huang B, Zhang G, Zhou JZ, Wang J, Digits JA, et al. Dihydroxyphenylisoindoline amides as orally bioavailable inhibitors of the heat shock protein 90 (hsp90) molecular chaperone. J Med Chem 2010;53(1):499-503.
36. Ortiz AG, Salcedo JM. Heat shock proteins as targets in oncology. Clin Transl Oncol 2010;12(3):166-73.
37. Banerji U. Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 2009;15(1):9-14.
38. Luo W, Sun W, Taldone T, Rodina A, Ciosis G. Heat shock protein 90 in neurodegenerative diseases. Mol Neurodegener 2010;5:24.
39. Peterson LB, Blagg BS. To fold or not to fold: modulation and consequences of Hsp90 inhibition. Future Med Chem 2009;1(2):267-83.
40. Rice JW, Veal JM, Fadden RP, Barabasz AF, Partridge JM, Barta TE, et al. Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis. Arthritis Rheum 2008;58:3765-75.
41. Soti C, Nagy E, Giricz Z, Vigh L, Csermely P, Ferdinandy P. Heat shock proteins as emerging therapeutic targets. Br J Pharmacol 2005;146:769-80.
42. Stephanou A, Latchman DS, Isenberg DA. The regulation of heat shock proteins and their role in systemic lupus erythematosus. Semin Arthritis Rheum 1998;28:155-62.
43. Jouret F, Devuyst O. CFTR and defective endocytosis: new insights in the renal phenotype of cystic fibrosis. Pflugers Arch 2009;457:1227-36.
44. Cowen LE, Steinback WJ. Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot Cell 2008;7:747-64.
45. Neckers L, Tatu U. Molecular chaperones in pathogen virulence: emerging new targets for therapy. Cell Host Microbe 2008;4:519-27.
46. Shonhai A. Plasmodial heat shock proteins: targets for chemotherapy. FEMS Immunol Med Microbiol 2010;58(1):61-74.
47. Tash JS, Chakrasali R, Jakkaraj SR, Hughes J, Smith SK, Hornbaker K, et al. Gamendazole, an orally active indazole carboxylic acid male contraceptive agent, targets Hsp90AB1 (Hsp90BETA) and EEF1A1 (eEf1A), and stimulates Il1a transcription in rat sertoli cells. Biol Reprod 2008;78:1139-52.
48. Velázquez Campoy A, Freire E. ITC in the post-genomic era...? Priceless. Biophys Chem 2005;115:115-24.
49. Krishnamurthy VM, Kaufman GK, Urbach AR, Gitlin I, Gudiksen KL, Weibel DB, et al. Carbonic anhydrase as a model for biophysical and physical-organic studies of proteins and protein-ligand binding. Chem Rev 2008;108(3): 946-1051.
50. Niesen FH, Berglund H, Vedadi M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc 2007;2:2212-21.
51. Ladbury JE. Application of isothermal titration calorimetry in the biological sciences: things are heating up! Biotechniques 2004;37(6):885-7.
52. Freyer MW, Lewis EA. Isothermal titration calorimetry: experimental design, data analysis, and probing macromolecule/ ligand binding and kinetic interactions. Methods Cell Biol 2008;84:79-113.
53. Cimmperman P, Matulis D. Protein thermal denaturation measurements via a fluorescent dye. In: Podjarny A, Dejaegere A, Kieffer B, editors. Biophysical approaches determining ligand binding to biomolecular targets. 1st ed. Cambridge: RSC; 2010. p. 247-74.
54. Zubrienė A, Matulienė J, Baranauskienė L, Jachno J, Torresan J, Michailovienė V, et al. Measurement of nanomolar dissociation constants by titration calorimetry and thermal shift assay - radicicol binding to hsp90 and ethoxzolamide binding to CAII. Int J Mol Sci 2009;10(6):2662-80.
55. Zubrienė A, Gutkowska M, Matulienė J, Chaleckis R, Michailovienė V, Voroncova A, et al. Thermodynamics of radicicol binding to human Hsp90 alpha and beta isoforms. Biophys Chem 2010;152:153-63.
56. Matulis D, Kranz JK, Salemme FR, Todd MJ. Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using ThermoFluor. Biochemistry 2005;44(13):5258-66.
57. Cikotienė I, Kazlauskas E, Matulienė J, Michailovienė V, Torresan J, Jachno J, et al.5-Aryl-4-(5-substituted-2,4-dihydroxyphenyl)-1,2,3-thiadiazoles as inhibitors of Hsp90 chaperone. Bioorg Med Chem Let 2009;19:1089-92.